Efficacy and Safety of Enteric-coated Mycophenolate Sodium in Heart Transplant Recipients

Novartis Pharmaceuticals

Overview

This purpose of this extension study of patients being treated with EC-MPS is to assess the long term safety of this medication.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

NONE

Conditions

Patients Successfully Completing the 12-month Treatment Period of the Core Study (de Novo Heart Recipients) Who Were Interested of Being Treated With EC-MPS

Interventions

EC-MPSDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: Patients who were participating in the core study CERL080A2401 and have successfully completed the first 12 months of the core study Exclusion Criteria: Patients who did not complete the 12-month core study CERL080A2401 Other protocol-defined inclusion/exclusion criteria may apply.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.